The Pulse series has firmly established itself as a bang-for-buck favourite since its inception in 2017 and that looks to be ...

Analysis shows most security risk sits in longtail open source images, with 98% of CVEs outside top projects & Critical flaws ...

In today’s Pharma Pulse, the FDA issues two high-stakes priority vouchers for cholesterol and cancer therapies, GSK leverages ...

Taiwan-based passive component giant Yageo continues to be affected by and respond to price hikes. Following Kemet's two ...

Two rail giants’ plans to become the first coast-to-coast railroad company through a massive merger is drawing interest from ...

In today’s Pharma Pulse, GoodRx slashes cash prices for the new Wegovy pill, a federal judge halts the 340B rebate pilot, and ...